Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATEMPT 2.0
NCT04893109Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2021
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab emtansine in breast cancer (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Clinically Relevant Toxicities at 18 weeks and Disease Free Survival at 72 months. Started Jun 2021; status: recruiting.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04893109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04893109.